Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Breast Cancer Research and Treatment|December 11, 2012
Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimenDenise A Yardley, Lowell Hart, Linda Bosserman, et al.
Clinical Breast Cancer|June 5, 2012
Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trialsVicente Valero, Eduard Vrdoljak, Binghe Xu, et al.
Cancer|October 12, 2011
Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozoleAdam M Brufsky, W Graydon Harker, J Thaddeus Beck, et al.
Cancers|July 9, 2022
Genomic Markers of CDK 4/6 Inhibitor Resistance in Hormone Receptor Positive Metastatic Breast CancerJin Sun Lee, Susan E Yost, Sierra Min Li, et al.
JAMA Health Forum|June 7, 2024
Race and Ethnicity Representation in Phase 2/3 Oncology Clinical Trial Publications: A Systematic ReviewKekoa Taparra, Ryan Benavente, Jonathan J Shih, et al.
Annals of Surgical Oncology|July 29, 2015
Toolbox to Reduce Lumpectomy Reoperations and Improve Cosmetic Outcome in Breast Cancer Patients: The American Society of Breast Surgeons Consensus ConferenceJeffrey Landercasper, Deanna Attai, Dunya Atisha, et al.
Cancer Research|August 7, 2012
The microculture-kinetic (MiCK) assay: the role of a drug-induced apoptosis assay in drug development and clinical careLinda Bosserman, Franklyn Prendergast, Roy Herbst, et al.
Breast Cancer Research : BCR|April 19, 2015
Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survivalDenise A Yardley, Peter A Kaufman, Weidong Huang, et al.
American Health & Drug Benefits|July 4, 2014
Defining Value in Cancer Care: AVBCC 2013 Steering Committee Report, Burt Zweigenhaft, Linda Bosserman, et al.
Nature Communications|November 18, 2020
Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)Sara A Hurvitz, Jennifer L Caswell-Jin, Katherine L McNamara, et al.
Pageof 2